Genmont Biotech Inc.

Genmont Biotech Incorporation

Feng-Ching Hsieh

Yi-Hsing Chen

Ying-Chen Lu

Ching-Hsiang Hsu

Ya-Hui Chen

Hui-Yu Huang

Tsuei-Yin Huang

Ying-Yu Wang

Po-Yung Chen

Ying-Chen Leu

Tu-Wen Yu

Jun-Sheng Li

Ching-Pei Chen

Ding-Ying Lai

Present invention features a novel use offor treating type 2 diabetes, wherein theisGMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicatedstrain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

[object Object]

Present invention features a method for controlling body weight, comprisingGMNL-263 with the deposition numbers of BCRC 910452 and CCTCC M 209263. Moreover, the invention also relates to a novel use of the composition or the isolatedstrain for controlling body weight, whose mechanism is inhibiting biosynthesis of lipids and reducing formation of lipid droplets so as to control body weight.

An isolatedstrain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolatedstrain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of thestrain GMNL-133 is also disclosed.

The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount ofstrain which is at least one selected from the group consisting of:GMNL-89 strain,GMNL-205 strain,GMNL-263 strain and a pharmaceutical acceptable vehicle. TheGMNL-205 strain andGMNL-263 strain are novel isolatedstrains. In addition, the invention also relates to a novel use of the composition or thestrains for improving the syndrome of diabetes and complication thereof.

Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof

Disclosed herein are twoisolates having anti-inflammatory activities and beneficial probiotic properties, i.e.,GMNL-76 andGMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The twoisolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.

A-containing product used for inhibiting dental diseases caused by bacteria is provided, which comprises a plurality offor inhibiting the growth of bacteria of dental diseases. Particularly, foods, oral hygiene products or oral treatment medicine containing thewhen being administered or applied to a user can inhibit or reduce the number of pathogens of dental caries and periodontal diseases in oral cavity of the user, thereby achieving the efficacy of preventing dental diseases, such as dental caries and periodontal diseases.

Growing community of inventors

Pingtung County, Taiwan

Feng-Ching Hsieh